News & Updates

In the treatment of patients with Parkinson disease (PD), nicotinamide riboside does not appear to confer beneficial effects and is even associated with worse clinical outcomes compared with placebo, according to a phase III trial.

Treatment with tozorakimab as an add-on to inhaled maintenance therapy helps lessen the frequency of moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations, and this benefit is observed in both former and current smokers.

Older patients with major depressive disorder (MDD) treated with active theta-burst stimulation (TBS) show no significantly greater reduction in Hamilton Depression Rating Scale (HAM-D) scores than those who received sham stimulation at week 6, according to a study.

Magnetic seizure therapy (MST) and electroconvulsive therapy (ECT) deliver similar effects on clinical outcomes in individuals with bipolar depression, reveals a study. However, MST is associated with fewer cognitive adverse effects.

In breast cancer survivors receiving aromatase inhibitors, vulvovaginal fractional carbon dioxide (CO2) laser therapy (CLT) does not appear to confer additional improvements in sexual or vaginal health outcomes, as shown in a study.

Activin A blockade with garetosmab suppresses heterotopic ossification in adults with the ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP), according to findings from the phase III OPTIMA trial that served as the basis for its Food and Drug Administration (FDA) approval.

Children hospitalized with human metapneumovirus (hMPV) infection experience substantial clinical burden, especially infants and those with underlying comorbidities, according to a study.

In children receiving myelosuppressive chemotherapy for cancer, prophylactic treatment with romiplostim helps reduce bleeding and the need for blood transfusion despite having no effect on the speed of platelet recovery, as shown in a study.